Completed PHASE2/PHASE3 INTERVENTIONAL NCT00036127

Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Updated 5 times since 2017 Last updated: Nov 7, 2013 Started: Apr 30, 2002 Primary completion: Jan 31, 2003 Completion: Jan 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Schizophrenia, this trial is completed. The trial is conducted by Otsuka Pharmaceutical Development & Commercialization, Inc. and has accumulated 5 data snapshots since 2002. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Data source: Otsuka Pharmaceutical Development & Commercialization, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Atlanta, United States , Beachwood, United States , Cerritos, United States , Charleston, United States , Chula Vista, United States , Hoffman Estates, United States , Houston, United States , Las Vegas, United States , Macon, United States and 6 more locations